Prostate cancer cells secrete soluble factors such as insulin‐like growth factor (IGF), platelet‐derived growth factor (PDGF), bone morphogenetic protein (BMP), Endothelin‐1 and PTHrP to promote osteoblast proliferation and differentiation, subsequently osteoblasts generate receptor activator of nuclear factor κB ligand (RANKL) and interleukin 6 (IL‐6) to activate osteoclastic bone resorption leading to the release of bone matrix‐embedded transforming growth factor beta (TGF‐β) and epidermal growth factor (EGF) to promote tumour growth (Fournier et al., 2015; Tang et al., 2009; Zhang, 2019). Here, IL6 is linked to prostate carcinoma.